PDF(Pubmed)
Abstract：
Cachexia is a condition characterized by substantial loss of body weight resulting from the depletion of skeletal muscle and adipose tissue. A considerable fraction of patients with advanced cancer, particularly those who have been diagnosed with pancreatic or gastric cancer, lung cancer, prostate cancer, colon cancer, breast cancer, or leukemias, are impacted by this condition. This syndrome manifests at all stages of cancer and is associated with an unfavorable prognosis. It heightens the susceptibility to surgical complications, chemotherapy toxicity, functional impairments, breathing difficulties, and fatigue. The early detection of patients with cancer cachexia has the potential to enhance both their quality of life and overall survival rates. Regarding this matter, blood biomarkers, although helpful, possess certain limitations and do not exhibit universal application. Additionally, the available treatment options for cachexia are currently limited, and there is a lack of comprehensive understanding of the underlying molecular pathways associated with this condition. Thus, this review aims to provide an overview of molecular mechanisms associated with cachexia and potential therapeutic targets for the development of effective treatments for this devastating condition.
摘要：
恶病质是一种特征在于由骨骼肌和脂肪组织的消耗导致的体重的显著损失的病症。相当一部分晚期癌症患者，特别是那些被诊断患有胰腺癌或胃癌的人，肺癌,前列腺癌,结肠癌,乳腺癌,或者白血病，受到这种情况的影响。这种综合征表现在癌症的所有阶段，并与不良预后有关。它增加了对手术并发症的敏感性，化疗毒性,功能障碍，呼吸困难,和疲劳。癌症恶病质患者的早期发现有可能提高他们的生活质量和总体生存率。关于这件事,血液生物标志物，虽然有用,具有一定的局限性，不表现出普遍的应用。此外,目前恶病质的可用治疗方案有限，并且缺乏对与这种情况相关的潜在分子途径的全面了解。因此，这篇综述旨在提供与恶病质相关的分子机制和潜在治疗靶点的概述，以开发这种破坏性疾病的有效治疗方法。
